MarketPulse

ARV-102

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas Wins Historic PROTAC Approval; Eyes Q1 2026 Results on May 12

Arvinas wins landmark FDA approval for VEPPANU, first PROTAC protein degrader for breast cancer, ahead of schedule. Reports Q1 2026 results May 12.
PFEARVNFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas to Showcase ARV-102 Parkinson's Data at Major Neurology Conference

Arvinas will present Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, at AD/PD 2026 conference in Copenhagen, with Phase 1b trial planned for progressive supranuclear palsy.
ARVNPhase 1 clinical trialParkinson's disease